NuvinkaDx Achieves Milestones for GeneProof and ALPCO's Diagnostic Solutions

NuvinkaDx Announces Significant Milestones

NuvinkaDx, a prominent player in the field of diagnostic solutions, has unveiled major advancements for its subsidiaries GeneProof and ALPCO. Both companies are at the forefront of developing innovative testing technologies aimed at improving healthcare outcomes. These milestones are a testament to NuvinkaDx's commitment to enhancing accessibility and efficiency in diagnostic processes.

GeneProof's Expansion in STI Testing

GeneProof, known for its wide array of in vitro diagnostic (IVD) and in vitro diagnostic regulation (IVDR) assays, has officially launched a suite of Sexually Transmitted Infection (STI) PCR assays on its myCROBE™ platform across Europe. This platform is designed to offer seamless sample-to-answer automation, significantly enhancing the testing experience for both laboratories and patients.

The newly introduced assays enable the simultaneous detection of common STI pathogens, which include Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma hominis, and Mycoplasma genitalium. Notably, GeneProof plans to expand its STI product line further, with additional tests for Trichomonas vaginalis, Gardnerella vaginalis, and Ureaplasma urealyticum/parvum set to be released soon. This expansion follows their earlier announcement in 2025 regarding an upgraded extraction kit for the myCROBE platform, which has greatly streamlined sample preparation and improved assay performance.

ALPCO's Regulatory Progress

In tandem, ALPCO has secured Health Canada licenses for its gastrointestinal (GI) diagnostics utilizing the flash chemiluminescent KleeYa® platform. The newly licensed tests, including a Calprotectin CLIA assay and a Pancreatic Elastase CLIA assay, will allow Canadian clinical laboratories to access advanced, highly sensitive automated tools. These tools are essential in diagnosing conditions like inflammatory bowel disease and exocrine pancreatic insufficiency (EPI).

Erik Allen, the CEO of NuvinkaDx, emphasized the significance of these milestones, stating, “These dual milestones reflect the strength of NuvinkaDx's diversified diagnostics strategy. GeneProof's expansion into STIs with the myCROBE platform in Europe, alongside ALPCO's regulatory achievements in Canada with KleeYa, perfectly align with our overarching mission to enhance clinical outcomes through accessible and high-performance testing solutions.”

Looking Ahead

NuvinkaDx continues to prioritize investment in automated solutions for both gastrointestinal and infectious diseases, demonstrating its dedication to meeting the shifting demands of the healthcare landscape. With these advancements, NuvinkaDx reinforces its position as a leader in diagnostic innovation, committed to delivering high-quality products that respond to the needs of laboratories, healthcare professionals, and patients worldwide.

For further details about NuvinkaDx's latest innovations and product offerings, visit NuvinkaDx's website.

About NuvinkaDx

ALPCO began its journey in 1991, establishing itself as an importer and distributor of immunoassay products for the North American life science markets. Over the years, it evolved into a leading provider of novel immunodiagnostic reagents tailored for specialty testing laboratories. A notable milestone occurred in 2022 when ALPCO merged with GeneProof, a Czech company specializing in molecular diagnostics. Founded in 2005, GeneProof offers an impressive portfolio of more than 50 IVDD and 6 IVDR PCR test kits focused on infectious diseases and genetic mutations, along with proprietary instrumentation for clinical labs of various sizes. In 2024, they rebranded under the name NuvinkaDx to reflect the unified vision and goals of both organizations. For more information, you can visit ALPCO or GeneProof.